CN115433102A - 一种反式-(1r,2r)-2-氨基环己烷羧酸乙酯盐酸盐的制备方法 - Google Patents
一种反式-(1r,2r)-2-氨基环己烷羧酸乙酯盐酸盐的制备方法 Download PDFInfo
- Publication number
- CN115433102A CN115433102A CN202211291234.7A CN202211291234A CN115433102A CN 115433102 A CN115433102 A CN 115433102A CN 202211291234 A CN202211291234 A CN 202211291234A CN 115433102 A CN115433102 A CN 115433102A
- Authority
- CN
- China
- Prior art keywords
- trans
- preparation
- acid
- aminocyclohexane
- carbonitrile
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 238000006243 chemical reaction Methods 0.000 claims abstract description 27
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 22
- 238000000034 method Methods 0.000 claims abstract description 17
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 claims abstract description 14
- RVGOKHBYNZPVGI-NKWVEPMBSA-N (1r,2r)-2-aminocyclohexane-1-carbonitrile Chemical compound N[C@@H]1CCCC[C@H]1C#N RVGOKHBYNZPVGI-NKWVEPMBSA-N 0.000 claims abstract description 12
- USQHEVWOPJDAAX-PHDIDXHHSA-N (1r,2r)-2-aminocyclohexane-1-carboxylic acid Chemical compound N[C@@H]1CCCC[C@H]1C(O)=O USQHEVWOPJDAAX-PHDIDXHHSA-N 0.000 claims abstract description 10
- DINLIZUFVHTMDX-UHFFFAOYSA-N 7-azabicyclo[4.1.0]heptane Chemical compound C1CCCC2NC21 DINLIZUFVHTMDX-UHFFFAOYSA-N 0.000 claims abstract description 9
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 9
- 239000002253 acid Substances 0.000 claims abstract description 8
- 239000003960 organic solvent Substances 0.000 claims abstract description 6
- 230000003301 hydrolyzing effect Effects 0.000 claims abstract description 5
- 238000005886 esterification reaction Methods 0.000 claims abstract description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 12
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 8
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims description 7
- 238000010438 heat treatment Methods 0.000 claims description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 5
- 239000008346 aqueous phase Substances 0.000 claims description 4
- 239000012071 phase Substances 0.000 claims description 4
- 238000007142 ring opening reaction Methods 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 3
- 239000003054 catalyst Substances 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 claims description 3
- 238000000746 purification Methods 0.000 claims description 3
- 238000010992 reflux Methods 0.000 claims description 3
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 claims description 2
- 239000003377 acid catalyst Substances 0.000 claims description 2
- 230000002378 acidificating effect Effects 0.000 claims description 2
- KXZJHVJKXJLBKO-UHFFFAOYSA-N chembl1408157 Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=CC=1C1=CC=C(O)C=C1 KXZJHVJKXJLBKO-UHFFFAOYSA-N 0.000 claims description 2
- 238000006460 hydrolysis reaction Methods 0.000 claims description 2
- 238000004537 pulping Methods 0.000 claims description 2
- ULAHYQPCISGAFW-UHFFFAOYSA-N [C-]#N.[SiH4] Chemical compound [C-]#N.[SiH4] ULAHYQPCISGAFW-UHFFFAOYSA-N 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 abstract description 4
- 230000003321 amplification Effects 0.000 abstract description 2
- 239000000543 intermediate Substances 0.000 abstract description 2
- 238000003199 nucleic acid amplification method Methods 0.000 abstract description 2
- 238000011084 recovery Methods 0.000 abstract description 2
- 230000032050 esterification Effects 0.000 abstract 1
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000012074 organic phase Substances 0.000 description 6
- 238000001816 cooling Methods 0.000 description 5
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical class [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 238000009795 derivation Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000012065 filter cake Substances 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- 125000004093 cyano group Chemical group *C#N 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- XMQSOBPCWYVZSW-SCLLHFNJSA-N ethyl (1r,2r)-2-aminocyclohexane-1-carboxylate;hydrochloride Chemical compound Cl.CCOC(=O)[C@@H]1CCCC[C@H]1N XMQSOBPCWYVZSW-SCLLHFNJSA-N 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- LEIMLDGFXIOXMT-UHFFFAOYSA-N trimethylsilyl cyanide Chemical compound C[Si](C)(C)C#N LEIMLDGFXIOXMT-UHFFFAOYSA-N 0.000 description 2
- -1 Beta-amino acid compounds Chemical class 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 150000001576 beta-amino acids Chemical class 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C253/00—Preparation of carboxylic acid nitriles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B57/00—Separation of optically-active compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C227/14—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof
- C07C227/18—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof by reactions involving amino or carboxyl groups, e.g. hydrolysis of esters or amides, by formation of halides, salts or esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C227/26—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing carboxyl groups by reaction with HCN, or a salt thereof, and amines, or from aminonitriles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C253/00—Preparation of carboxylic acid nitriles
- C07C253/32—Separation; Purification; Stabilisation; Use of additives
- C07C253/34—Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
本发明公开了一种反式‑(1R,2R)‑2‑氨基环己烷羧酸乙酯盐酸盐的制备方法,属于医药中间体技术领域。1)7‑氮杂双环[4.1.0]庚烷与氰化试剂在B(C6F5)3存在下,升温加压反应,得到反式‑2‑氨基环己烷‑1‑甲腈;2)与L‑DBTA在有机溶剂进行对映异构体拆分得到反式‑(1R,2R)‑2‑氨基环己烷‑1‑甲腈;3)接着在酸条件下水解得到反式‑2‑氨基环己烷羧酸;4)最后与乙醇在氯化亚砜作用下酯化得到反式‑(1R,2R)‑2‑氨基环己烷羧酸乙酯盐酸盐。该方法反应操作简便,得到产品大于99.5%ee,拆分剂L‑DBTA回收率为85%,成本低廉,具备潜在的工业化放大前景。
Description
技术领域
本发明涉及一种反式-(1R,2R)-2-氨基环己烷羧酸乙酯盐酸盐的制备方法,属于医药中间体技术领域。
背景技术
反式-(1R,2R)-2-氨基环己烷羧酸乙酯盐酸盐,CAS 28250-14-8,英文名称Ethyltrans-(1R,2R)-2-aminocyclohexanecarboxylate,为一种β-环状氨基酸。传统肽类药物在体内环境下易水解,具有不稳定性,以β-氨基酸为基本单位β-肽相比传统α-肽,引入特殊的结构进行构象限制,从而使药代动力学参数更加良好,体内环境保留时间更长,可克服传统肽类药物对酶不稳定的缺点,为药物设计提供了系列新活性候选药物分子,蕴藏着非常大药物开发价值。β-氨基酸类化合物具有广泛的生物活性,如调节蛋白相互作用、抗病毒、抗菌、细胞穿透性能、受体激动剂和激素调节剂等。
文献[European Journal of Organic Chemistry,2003,4,721-726]路线用六步得到反式-2-氨基环己烷羧酸,其中需要将顺式转化为反式,其构象还是混合(即不纯)。文献[Journal of Organic Chemistry,2000,vol.65,#15,p.4766-4769]同样是需要将顺式转化为反式。
因此,仍需对反式-2-氨基环己烷羧酸乙酯盐酸盐反应路线进行深入研究,避免顺式转化反式的反应,从而规避转化率及相关纯化问题,同时降低成本,得到大于99.5%eeβ-环状氨基酸,并提供一种原料易得、稳定的反应路线,以满足日益增长的市场需求。
发明内容
为了克服上述技术缺陷,本发明公开了一种反式-(1R,2R)-2-氨基环己烷羧酸乙酯盐酸盐的制备方法。1)7-氮杂双环[4.1.0]庚烷与氰化试剂在B(C6F5)3存在下,升温加压反应,得到反式-2-氨基环己烷-1-甲腈;2)与L-DBTA在有机溶剂进行对映异构体拆分得到反式-(1R,2R)-2-氨基环己烷-1-甲腈;3)接着在酸条件下水解得到反式-2-氨基环己烷羧酸;4)最后与乙醇在氯化亚砜作用下酯化得到反式-(1R,2R)-2-氨基环己烷羧酸乙酯盐酸盐。该方法反应操作简便,得到产品大于99.5%ee,拆分剂L-DBTA回收率为85%,成本低廉,具备潜在的工业化放大前景。
本发明所述一种反式-(1R,2R)-2-氨基环己烷羧酸乙酯盐酸盐的制备方法,包括如下步骤:
1)开环反应:7-氮杂双环[4.1.0]庚烷与氰化试剂,在酸性催化剂存在下,有机溶剂中高温反应得到反式-2-氨基环己烷-1-甲腈;
2)成盐拆分:将L-DBTA与反式-2-氨基环己烷-1-甲腈,在乙醇溶剂中反应,过滤得到反式-(1R,2R)-2-氨基环己烷-1-甲腈与L-DBTA络合物,随后加酸调至酸性,溶剂萃取,水相保留;
3)水解反应:将第2)步中水相加酸,升温水解,得到反式-(1R,2R)-2-氨基环己烷羧酸;
4)酯化反应:将反式-2-氨基环己烷羧酸与乙醇,在氯化亚砜存在下,升温回流反应,得到反式-(1R,2R)-2-氨基环己烷羧酸乙酯盐酸盐。
上述四步反应,采用反应方程式表示如下:
进一步地,在上述技术方案中,步骤1)所述氰化试剂选自氰化钠、氰化钾或三甲基氰硅烷(TMSCN)。
进一步地,在上述技术方案中,步骤1)所述酸性催化剂选自B(C6F5)3,有机溶剂选自选自二氧六环、乙腈、DMSO中的任意一种与水混合物。开环时体系添加四正丁基氟化铵时,可进一步缩短反应时间。
进一步地,在上述技术方案中,步骤1)所述7-氮杂双环[4.1.0]庚烷与氰化试剂摩尔比为1:1.4-1.7。
进一步地,在上述技术方案中,步骤2)所述反式-2-氨基环己烷-1-甲腈与L-DBTA摩尔比为1:0.45-0.50。
进一步地,在上述技术方案中,步骤3)所述酸选自60-65%浓硫酸或30%盐酸,反应温度选自60-85℃。
进一步地,在上述技术方案中,步骤4)所述反式-2-氨基环己烷羧酸、乙醇与氯化亚砜摩尔比例为1:10-15:1.15-1.20;后处理纯化采用甲基叔丁基醚或异丙醚打浆。
发明有益效果
A、通过氰基对7-氮杂双环[4.1.0]庚烷开环,完全得到反式化合物;高温高压反应时通过选择特殊催化剂,氰化试剂用量更少,反应更为彻底。
B、采用L-DBTA这种对映体拆分剂,通过结晶拆分法一次就可得到单一手性的对映体。且L-DBTA可回收套用。
C、采用浓硫酸水解氰基更彻底,相比用强碱水解,酰胺及杂质更少,收率更高。
具体实施例
下面通过具体实例对本发明进行进一步说明。这些实施例应理解为仅用于说明本发明而不用于限制本发明的保护范围。在阅读了本发明记载的内容之后,本领域技术人员可以对本发明作各种改动或修改,这些等效变化和修改同样落入本发明权利要求所限定的范围。
实施例1:
将7-氮杂双环[4.1.0]庚烷97.2g(1.0mol,1eq)、NaCN 83.3g(1.7mol,1.7eq)、B(C6F5)310.2g(0.02mol,0.02eq)和30%乙腈水溶液600mL投入到高压反应釜,密闭下升温至120-130℃反应过夜。检测反应完毕降温至0℃,加入30%NaOH调节pH碱性,减压浓缩后,二氯甲烷萃取,饱和碳酸钠洗涤,有机相浓缩得到反式-2-氨基环己烷-1-甲腈104.6g,收率84.2%,GC 95.4%。GC-MS[M+H]+=125.1;1HNMR(400MHz,CDCl3):3.44-3.47(m,1H),2.42-2.46(m,1H),1.10-2.20(m,10H).
实施例2
将7-氮杂双环[4.1.0]庚烷97.2g(1.0mol,1eq)、KCN 91.2g(1.4mol,1.4eq)、B(C6F5)310.2g(0.02mol,0.02eq)和30%乙腈水溶液600mL投入到高压反应釜,密闭下升温至120-130℃反应过夜。检测反应完毕,降温至0℃,加入30%NaOH调节pH碱性,减压浓缩后,二氯甲烷萃取,饱和碳酸钠洗涤,有机相浓缩得到反式-2-氨基环己烷-1-甲腈108.7g。收率87.5%,GC 96.2%。
实施例3:
将7-氮杂双环[4.1.0]庚烷97.2g(1.0mol,1eq)、TMSCN148.8g(1.5mol,1.5eq)、B(C6F5)310.2g(0.02mol,0.02eq)、四丁基氟化铵52.3g(0.2mol,0.2eq)和80%二氧六环水溶液500mL投入到高压反应釜内,密闭下升温至120-130℃反应过夜。检测反应完毕,降温至0℃,加入30%NaOH调节pH碱性,减压浓缩后,二氯甲烷萃取,饱和碳酸钠洗涤,有机相浓缩得到反式-2-氨基环己烷-1-甲腈102.7g。收率82.7%,GC 94.5%。
实施例4
向反应瓶内投入反式-2-氨基环己烷-1-甲腈99.4g(0.8mol,1eq)和无水乙醇350mL,搅拌溶清后,室温下2小时内滴加入L-DBTA 150.4g(0.40mol,0.50eq)和无水乙醇400mL混合溶液。滴加完毕,继续搅拌2小时。过滤,滤饼少量冷乙醇淋洗,得到反式-(1R,2R)-2-氨基环己烷-1-甲腈与L-DBTA络合物。将滤饼重新投入反应瓶内,加入甲基叔丁基醚和10%盐酸调节pH=1.0-1.5,分层,有机相为拆分剂及少量杂质(可回收),保留水相加入30%NaOH调节pH=12-13,二氯甲烷萃取,有机相浓缩,得到反式-(1R,2R)-2-氨基环己烷-1-甲腈39.2g,收率39.5%,GC99.5%,99.6%ee。
实施例5
向反应瓶内加入反式-(1R,2R)-2-氨基环己烷-1-甲腈49.7g(0.4mol,1eq)和甲苯200mL,升温至60℃,滴加65%浓硫酸162.8g(1mol,2.5eq),继续升温至75-80℃反应6小时,降温至50℃,分去有机相,保留水相,水相加入10%KOH调节等电点pH=6.72-6.86,随后降温至10℃,产品析出,过滤得到反式-2-氨基环己烷羧酸52.5g;收率91.7%,99.5%ee(衍生法测定)。1HNMR(400MHz,CD3OD):3.45-3.49(m,1H),2.63-2.66(m,1H),1.10-2.20(m,8H)
实施例5
向反应瓶内加入反式-(1R,2R)-2-氨基环己烷-1-甲腈49.7g(0.4mol,1eq)、30%盐酸300mL和甲醇50mL混合。升温至回流反应17小时,降温后减压浓缩除掉甲醇,加入MTBE萃取杂质,水相加入10%KOH调节等电点pH=6.72-6.86,随后降温至10℃,产品析出,过滤,滤饼得到反式-2-氨基环己烷羧酸50.5g;收率88.2%,99.4%ee(衍生法)。
实施例6
向反应瓶内加入反式-2-氨基环己烷羧酸50.1g(0.35mol,1eq)与乙醇300mL混合,20-30℃缓慢滴加氯化亚砜50g(0.42mol,1.2eq),随后升温回流8小时,减压浓缩至不流液,加入MTBE打浆得到反式-(1R,2R)-2-氨基环己烷羧酸乙酯盐酸盐67.1g。收率92.3%,99.5%ee(衍生法,绝对构型通过与标准品对照)。1HNMR(400MHz,CDCl3):8.50(s,3H),4.23-4.26(m,2H),3.38-3.41(m,1H),2.72-2.76(m,1H),2.38-1.23(m,11H).
以上所述,仅为本发明较佳的具体实施方式,但本发明的保护范围并不局限于此,任何熟悉本技术领域的技术人员在本发明披露的技术范围内,根据本发明的技术方案及其发明构思加以等同替换或改变,都应涵盖在本发明的保护范围之内。
Claims (8)
1.一种反式-(1R,2R)-2-氨基环己烷羧酸乙酯盐酸盐的制备方法,其特征在于,包括如下步骤:
1)开环反应:7-氮杂双环[4.1.0]庚烷与氰化试剂,在酸性催化剂存在下,有机溶剂中高温反应得到反式-2-氨基环己烷-1-甲腈;
2)成盐拆分:将L-DBTA与反式-2-氨基环己烷-1-甲腈,在乙醇溶剂中反应,过滤得到反式-(1R,2R)-2-氨基环己烷-1-甲腈与L-DBTA络合物,随后加酸调至酸性,溶剂萃取,水相保留;
3)水解反应:将第2)步中水相加酸,升温水解,得到反式-(1R,2R)-2-氨基环己烷羧酸;
4)酯化反应:将反式-2-氨基环己烷羧酸与乙醇,在氯化亚砜存在下,升温回流反应,得到反式-(1R,2R)-2-氨基环己烷羧酸乙酯盐酸盐。
2.根据权利要求1所述反式-(1R,2R)-2-氨基环己烷羧酸乙酯盐酸盐的制备方法,其特征在于:步骤1)所述氰化试剂选自氰化钠、氰化钾或三甲基氰硅烷。
3.根据权利要求1所反式-(1R,2R)-2-氨基环己烷羧酸乙酯盐酸盐的制备方法,其特征在于:步骤1)所述酸性催化剂选自B(C6F5)3,有机溶剂选自二氧六环、乙腈、DMSO中的任意一种与水混合物。
4.根据权利要求1所述反式-(1R,2R)-2-氨基环己烷羧酸乙酯盐酸盐的制备方法,其特征在于:步骤1)所述7-氮杂双环[4.1.0]庚烷与氰化试剂摩尔比为1:1.4-1.7。
5.根据权利要求1所述反式-(1R,2R)-2-氨基环己烷羧酸乙酯盐酸盐的制备方法,其特征在于:步骤2)所述反式-2-氨基环己烷-1-甲腈与L-DBTA摩尔比为1:0.45-0.50。
6.根据权利要求1所述反式-(1R,2R)-2-氨基环己烷羧酸乙酯盐酸盐的制备方法,其特征在于:步骤3)所述酸选自60-65%浓硫酸或30%盐酸,反应温度选自60-85℃。
7.根据权利要求1所述反式-(1R,2R)-2-氨基环己烷羧酸乙酯盐酸盐的制备方法,其特征在于:步骤4)所述反式-2-氨基环己烷羧酸、乙醇与氯化亚砜摩尔比例为1:10-15:1.15-1.20;
8.根据权利要求1所述反式-(1R,2R)-2-氨基环己烷羧酸乙酯盐酸盐的制备方法,其特征在于:步骤4)后处理纯化时,采用甲基叔丁基醚或异丙醚打浆。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211291234.7A CN115433102B (zh) | 2022-10-16 | 2022-10-16 | 一种反式-(1r,2r)-2-氨基环己烷羧酸乙酯盐酸盐的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211291234.7A CN115433102B (zh) | 2022-10-16 | 2022-10-16 | 一种反式-(1r,2r)-2-氨基环己烷羧酸乙酯盐酸盐的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115433102A true CN115433102A (zh) | 2022-12-06 |
CN115433102B CN115433102B (zh) | 2024-02-27 |
Family
ID=84252527
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211291234.7A Active CN115433102B (zh) | 2022-10-16 | 2022-10-16 | 一种反式-(1r,2r)-2-氨基环己烷羧酸乙酯盐酸盐的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115433102B (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140024650A1 (en) * | 2011-04-05 | 2014-01-23 | Takeda Pharmaceutical Company Limited | Sulfonamide derivative and use thereof |
CN114426497A (zh) * | 2022-01-27 | 2022-05-03 | 泰州精英化成医药科技有限公司 | 一种反式-4-氨基环己甲酸盐酸盐的制备方法 |
-
2022
- 2022-10-16 CN CN202211291234.7A patent/CN115433102B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140024650A1 (en) * | 2011-04-05 | 2014-01-23 | Takeda Pharmaceutical Company Limited | Sulfonamide derivative and use thereof |
CN114426497A (zh) * | 2022-01-27 | 2022-05-03 | 泰州精英化成医药科技有限公司 | 一种反式-4-氨基环己甲酸盐酸盐的制备方法 |
Non-Patent Citations (1)
Title |
---|
ATTILA MARIO REMETE等: "Alicyclic β- and γ-Amino Acids: Useful Scaffolds for the Stereocontrolled Access to Amino Acid-Based Carbocyclic Nucleoside Analogs", MOLECULES, vol. 24, no. 161, pages 24010161 * |
Also Published As
Publication number | Publication date |
---|---|
CN115433102B (zh) | 2024-02-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN114014787B (zh) | 一种制备(2s,3r)-对甲砜基苯丝氨酸乙酯的不对称合成方法 | |
CN110078644B (zh) | 一种[2-[1-(Fmoc-氨基)乙氧基]乙氧基]乙酸的制备方法 | |
CN115160158B (zh) | 一种手性叔亮氨醇的制备方法 | |
CN114621068A (zh) | 3-羟基-1-金刚烷甲基酮的制备方法及合成沙格列汀的方法 | |
CN111170878B (zh) | 一种制备d-型或l-型叔亮氨酸的方法 | |
CN106748966B (zh) | 一种雷米普利关键中间体的合成方法 | |
CN115433102A (zh) | 一种反式-(1r,2r)-2-氨基环己烷羧酸乙酯盐酸盐的制备方法 | |
CN107118073A (zh) | 二醇催化制备二氯卤代烷的方法 | |
CN111333505A (zh) | 制备长链脂肪二酸单苄酯的方法及其应用 | |
CN114702425B (zh) | (s)-2-氨基-(s)-3-[吡咯烷酮-2’]丙氨酸衍生物及中间体的制备方法 | |
WO2022199378A1 (zh) | 贝派度酸原料药的合成方法 | |
CN112225666B (zh) | 一种(r)-3-氨基-4-(2,4,5-三氟苯基)丁酸甲酯的制备方法 | |
CN110950818B (zh) | 顺式-2,6-二甲基吗啉的纯化方法 | |
CN111100042B (zh) | 一种2-甲氧基-5-磺酰胺基苯甲酸的制备方法 | |
CN104370953B (zh) | 一种(r)‑叔丁基二甲基硅氧基‑戊二酸单酯的制备方法 | |
CN102070468B (zh) | β-肾上腺激动素莱克多巴胺的合成方法 | |
CN106748725B (zh) | 一种4-氯-2-氟-苯丙酸的制备方法 | |
CA2345068C (en) | Process for the preparation of .alpha.,.alpha.-dimethylphenylacetic acid from .alpha.,.alpha.-dimethylbenzyl cyanide under normal pressure | |
CN115650852B (zh) | 一种十八烷二酸单叔丁酯的制备方法 | |
CN111662233B (zh) | 一种一步法合成4-氯-1h-咪唑-2-羧酸乙酯的方法 | |
CN114436877B (zh) | 一种抗心衰药物沙库巴曲的合成工艺 | |
CN116514646A (zh) | 一种苯丙酮酸的制备方法 | |
CN113527117A (zh) | Aeea的制备方法 | |
CN111039838A (zh) | 一种3-乙酰巯基-2-甲基丙酸的制备方法 | |
CN111892478A (zh) | 一种沙格列汀中间体的合成方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A method for preparing trans - (1R, 2R) -2-aminocyclohexanecarboxylic acid ethyl ester hydrochloride Granted publication date: 20240227 Pledgee: Dalian Branch of Bank of Communications Co.,Ltd. Pledgor: Dalian Shuangbo Pharmaceutical Chemical Co.,Ltd. Registration number: Y2024980026072 |